1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biosimulation Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing emphasis on research of personalized medicine
5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
5.1.2. Restraints
5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
5.1.3. Opportunities
5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
5.1.3.2. Rising investments for drug developments and drug testings
5.1.4. Challenges
5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
5.2. Market Segmentation Analysis
5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
5.2.2. Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
5.2.3. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
5.2.4. Application: Increasing application of biosimulation for drug development
5.3. Market Trend Analysis
5.3.1. Significant investments in drug development and collaborative activities to expand the usage of biosimulation in the Americas
5.3.2. Government initiatives to encourage the adoption of innovative technologies in pharmaceutical research in the APAC
5.3.3. Increasing clinical trials and drug development activities expanding the scope of biosimulation in the EMEA region
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
6. Biosimulation Market, by Offering
6.1. Introduction
6.2. Services
6.3.1. Contract Services
6.3.2. In-House Services
6.3. Software
6.4.1. Molecular Modeling & Simulation Software
6.4.2. PBPK Modeling & Simulation Software
6.4.3. PK/PD Modeling & Simulation Software
6.4.4. Toxicity Prediction Software
6.4.5. Trial Design Software
7. Biosimulation Market, by Delivery Model
7.1. Introduction
7.2. Ownership Models
7.3. Subscription Models
8. Biosimulation Market, by End-User
8.1. Introduction
8.2. Contract Research Organizations
8.3. Pharmaceutical & Biotechnology Companies
8.4. Regulatory Authorities
8.5. Research Institutes
9. Biosimulation Market, by Application
9.1. Introduction
9.2. Drug Development
9.3.1. Clinical Trials
9.3.2. Preclinical Testing
9.3.3.1. ADME/Tox
9.3.3.2. PK/PD
9.3. Drug Discovery
9.4.1. Lead Identification & Optimization
9.4.2. Target Identification & Validation
10. Americas Biosimulation Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Biosimulation Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Biosimulation Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Merger & Acquisition
13.3.1.1. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
13.3.1.2. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
13.3.1.3. Resolution Medical Acquires LifeTec Group
13.3.2. Agreement, Collaboration, & Partnership
13.3.2.1. Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
13.3.2.2. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
13.3.2.3. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
13.3.2.4. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
13.3.2.5. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
13.3.3. New Product Launch & Enhancement
13.3.3.1. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
13.3.3.2. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
13.3.3.3. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
13.3.3.4. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
13.3.4. Investment & Funding
13.3.4.1. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life
13.3.5. Award, Recognition, & Expansion
13.3.5.1. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
13.3.5.2. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Advanced Chemistry Development, Inc.
14.1.2. Aitia
14.1.3. Allucent
14.1.4. Applied BioMath, LLC
14.1.5. Biomed Simulation, Inc.
14.1.6. BioSimulation Consulting Inc.
14.1.7. Cadence Design Systems, Inc.
14.1.8. Cell Works Group, Inc.
14.1.9. Certara, Inc.
14.1.10. Chemical Computing Group ULC
14.1.11. Compugen Ltd.
14.1.12. Crystal Pharmatech Co., Ltd.
14.1.13. Dassault Systèmes SE
14.1.14. Genedata AG
14.1.15. Immunetrics Inc
14.1.16. In Silico Biosciences, Inc.
14.1.17. INOSIM Software GmbH
14.1.18. Instem PLC
14.1.19. Laboratory Corporation of America Holdings
14.1.20. Model Vitals
14.1.21. Physiomics PLC
14.1.22. Quotient Sciences Limited
14.1.23. Resolution Medical
14.1.24. Rosa & Co LLC
14.1.25. Schrodinger, Inc.
14.1.26. Simulations Plus, Inc.
14.1.27. Thermo Fisher Scientific Inc.
14.1.28. VeriSIM Life.
14.1.29. VIRTUALMAN
14.1.30. Yokogawa Electric Corporation
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing